Epidemiologist Nicholas Hulscher reported that in the largest study of Ivermectin and Mebendazole anti-parasitic treatments, nearly half of the patients in the study reported a disappearance of the cancer or tumor regression. He wrote that 32.8% of the study participants showed no more evidence of disease after 6 months, 15.6% reported tumor regression and 36.1% reported that the disease had stabilized and was no longer spreading.

The clinical program evaluation included 197 cancer patients, with 122 completing a follow-up survey at about six months (61.9% response rate).

The cancer patients were prescribed compounded ivermectin–mebendazole, with each capsule containing 25 mg ivermectin and 250 mg mebendazole—most commonly taken at 1–2 capsules per day.

NOTE: The Need To Know News does not endorse any medical treatments, but instead reports the news. Please consult your own medical health experts before engaging in any medical treatments.

Report from epidemiologist Nicholas Hulscher: